Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis

NCT00124943 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Restenosis

Interventions

DRUG: Nanoparticle Paclitaxel

Sponsor

Celgene Corporation